THERANOSTEC INC
Elk Grove, CA · Biotech · Private
Transformable Nano-Theranostics (TNTs) — nanoparticles that change size and charge in response to tumor acidity for imaging-guided surgical and therapeutic intervention in head and neck cancer
- Grants
- $6.9M
- 11 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Extremely long tumor retention, on-demand releasing Nano-Taxel for eradicating ovarian cancers | $291,894 | |
| Federal grant | Department of Health and Human Services · Phase I · Ninja Theranostics for overcoming the drug delivery barriers to pediatric brain tumor | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Transformable nano-theranostics for image-guided interventions in head and neck squamous cell carcinoma | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Extremely long tumor retention, on-demand releasing Nano-Taxel for eradicating ovarian cancers | $503,046 | |
| Federal grant | Department of Health and Human Services · Phase I · Transformable nano-theranostics for image-guided interventions in head and neck squamous cell carcinoma | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Extremely long tumor retention, on-demand releasing Nano-Taxel for eradicating ovarian cancers | $1,496,599 | |
| Federal grant | Department of Health and Human Services · Phase II · Transformable Theranostics for imaging-guided interventions in head and neck squamous cell carcinoma | $480,254 | |
| Federal grant | Department of Health and Human Services · Phase II · Transformable Theranostics for imaging-guided interventions in head and neck squamous cell carcinoma | $1,330,042 | |
| Federal grant | Department of Health and Human Services · Phase I · Sub-100 nm and scalable self-therapeutic nanoparticles to target autophagy in pancreatic cancer | $399,999 | |
| Federal grant | Department of Health and Human Services · Phase II · Transformable Theranostics for imaging-guided interventions in head and neck squamous cell carcinoma | $849,788 | |
| Federal grant | Department of Health and Human Services · Phase II · Transformable Theranostics for imaging-guided interventions in head and neck squamous cell carcinoma | $719,958 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1588 | CHEMILY, LLC | — | — |
| 1589 | REGENTIS BIOMATERIALS LTD. | — | $6.5M |
| 1590 | LEXEO Therapeutics LLC | — | — |
| 1591 | THERANOSTEC INC | — | — |
| 1592 | KURE. AI, INC. | — | — |
| 1593 | INSILICOS | — | — |
| 1594 | FAIRBANKS PHARMACEUTICALS | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.